Please use this identifier to cite or link to this item:
https://doi.org/10.1186/s13045-015-0163-z
DC Field | Value | |
---|---|---|
dc.title | Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: A clinicopathologic analysis of 61 patients | |
dc.contributor.author | Loghavi, S | |
dc.contributor.author | Alayed, K | |
dc.contributor.author | Aladily, T.N | |
dc.contributor.author | Zuo, Z | |
dc.contributor.author | Ng, S.-B | |
dc.contributor.author | Tang, G | |
dc.contributor.author | Hu, S | |
dc.contributor.author | Yin, C.C | |
dc.contributor.author | Miranda, R.N | |
dc.contributor.author | Medeiros, L.J | |
dc.contributor.author | Khoury, J.D | |
dc.date.accessioned | 2020-10-27T05:40:21Z | |
dc.date.available | 2020-10-27T05:40:21Z | |
dc.date.issued | 2015 | |
dc.identifier.citation | Loghavi, S, Alayed, K, Aladily, T.N, Zuo, Z, Ng, S.-B, Tang, G, Hu, S, Yin, C.C, Miranda, R.N, Medeiros, L.J, Khoury, J.D (2015). Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: A clinicopathologic analysis of 61 patients. Journal of Hematology and Oncology 8 (1) : 65. ScholarBank@NUS Repository. https://doi.org/10.1186/s13045-015-0163-z | |
dc.identifier.issn | 17568722 | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/180909 | |
dc.description.abstract | Background: Plasmablastic lymphoma (PBL) is a rare aggressive neoplasm with lymphoid and plasmacytic differentiation that is commonly associated with immunodeficiency and an unfavorable prognosis. Clinicopathologic features have been largely derived from cases reports and small series with limited outcome analyses. Patients and methods: The demographic, clinicopathologic features, and clinical outcomes of a cohort of 61 patients with PBL were reviewed and analyzed. Results: Patients had a median age of 49 years (range 21-83 years) and most (49/61; 80 %) were men. Human immunodeficiency virus (HIV) status was available for 50 patients: 20 were HIV-positive and 30 HIV-negative. Twenty-three patients were immunocompetent. Abdominal/gastrointestinal complaints were the most common presenting symptoms, reported in 14 of 47 (30 %) of patients. At presentation, 24 of 43 (56 %) patients had stage III or IV disease. Epstein-Barr virus (EBV) was detected in 40 of 57 (70 %) cases. MYC rearrangement was identified in 10/15 (67 %) cases assessed, and MYC overexpression was seen in all cases assessed regardless of MYC rearrangement status. HIV-positive patients were significantly younger than those who were HIV-negative (median 42 vs. 58 years; p∈=∈0.006). HIV-positive patients were also significantly more likely to have EBV-positive disease compared with HIV-negative patients (19/19, 100 % vs. 15/29, 52 %; p∈=∈0.002). Patients who received CHOP chemotherapy tended to have better overall survival (OS) compared with those who received hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) (p∈=∈0.078). HIV status had no impact on OS. Patients with EBV-positive PBL had a better event-free survival (EFS) (p∈=∈0.047) but not OS (p∈=∈0.306). Notably, OS was adversely impacted by age ge;50 years (p∈=∈0.013), stage III or IV disease (p∈=∈<0.001), and lymph node involvement (p∈=∈0.008). Conclusions: The most significant prognostic parameters in patients with PBL are age, stage, and, to a lesser extent, EBV status. In this study, two-thirds of PBL cases assessed were associated with MYC rearrangement and all showed MYC overexpression. © 2015 Loghavi et al. | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.source | Unpaywall 20201031 | |
dc.subject | cyclophosphamide | |
dc.subject | dexamethasone | |
dc.subject | doxorubicin | |
dc.subject | etoposide | |
dc.subject | prednisone | |
dc.subject | vincristine | |
dc.subject | antineoplastic agent | |
dc.subject | abdominal pain | |
dc.subject | adult | |
dc.subject | age distribution | |
dc.subject | aged | |
dc.subject | Article | |
dc.subject | cancer chemotherapy | |
dc.subject | cancer prognosis | |
dc.subject | cancer staging | |
dc.subject | cancer survival | |
dc.subject | carcinogenesis | |
dc.subject | clinical evaluation | |
dc.subject | cohort analysis | |
dc.subject | colorimetry | |
dc.subject | controlled study | |
dc.subject | correlational study | |
dc.subject | cytogenetics | |
dc.subject | diarrhea | |
dc.subject | epistaxis | |
dc.subject | Epstein Barr virus | |
dc.subject | Epstein Barr virus infection | |
dc.subject | event free survival | |
dc.subject | female | |
dc.subject | fluorescence in situ hybridization | |
dc.subject | follow up | |
dc.subject | gastrointestinal symptom | |
dc.subject | gene overexpression | |
dc.subject | gene rearrangement | |
dc.subject | health impact assessment | |
dc.subject | histopathology | |
dc.subject | human | |
dc.subject | Human immunodeficiency virus infection | |
dc.subject | human tissue | |
dc.subject | immunocompromised patient | |
dc.subject | immunophenotyping | |
dc.subject | major clinical study | |
dc.subject | male | |
dc.subject | nose ulcer | |
dc.subject | oncogene myc | |
dc.subject | outcome assessment | |
dc.subject | overall survival | |
dc.subject | plasmablastic lymphoma | |
dc.subject | rectum hemorrhage | |
dc.subject | rhinorrhea | |
dc.subject | sinusitis | |
dc.subject | very elderly | |
dc.subject | virus detection | |
dc.subject | age | |
dc.subject | cancer staging | |
dc.subject | complication | |
dc.subject | Epstein Barr virus infection | |
dc.subject | genetics | |
dc.subject | middle aged | |
dc.subject | pathology | |
dc.subject | plasmablastic lymphoma | |
dc.subject | treatment outcome | |
dc.subject | young adult | |
dc.subject | Adult | |
dc.subject | Age Factors | |
dc.subject | Aged | |
dc.subject | Aged, 80 and over | |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject | Cohort Studies | |
dc.subject | Epstein-Barr Virus Infections | |
dc.subject | Female | |
dc.subject | Humans | |
dc.subject | Male | |
dc.subject | Middle Aged | |
dc.subject | Neoplasm Staging | |
dc.subject | Plasmablastic Lymphoma | |
dc.subject | Treatment Outcome | |
dc.subject | Young Adult | |
dc.type | Article | |
dc.contributor.department | PATHOLOGY | |
dc.description.doi | 10.1186/s13045-015-0163-z | |
dc.description.sourcetitle | Journal of Hematology and Oncology | |
dc.description.volume | 8 | |
dc.description.issue | 1 | |
dc.description.page | 65 | |
dc.published.state | Published | |
Appears in Collections: | Elements Staff Publications |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_1186_s13045-015-0163-z.pdf | 2.03 MB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License